{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:14:33Z","timestamp":1759335273052,"version":"3.37.3"},"reference-count":21,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0801-z","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T14:03:26Z","timestamp":1575468206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Rapid and sustained response to immune checkpoint inhibition in cutaneous squamous cell carcinoma after allogenic hematopoietic cell transplant for s\u00e9zary syndrome"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6697-3516","authenticated-orcid":false,"given":"Karam","family":"Khaddour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Musiek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn A.","family":"Cornelius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farrokh","family":"Dehdashti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Westervelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Fields","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Ansstas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,12,4]]},"reference":[{"key":"801_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","volume":"125","author":"CF Hughes","year":"2015","unstructured":"Hughes CF, Khot A, McCormack C, Lade S, Westerman DA, Twigger R, Buelens O, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy. Blood. 2015;125:71\u201381.","journal-title":"Blood."},{"issue":"19","key":"801_CR2","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, et al. Phase II study of the efficacy and safety of Pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125\u201332.","journal-title":"J Clin Oncol"},{"issue":"3","key":"801_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","volume":"130","author":"PL Zinzani","year":"2017","unstructured":"Zinzani PL, Ribrag V, et al. Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma. Blood. 2017;130(3):267\u201370.","journal-title":"Blood."},{"issue":"23","key":"801_CR4","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","volume":"34","author":"MG Roemer","year":"2016","unstructured":"Roemer MG, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016;34(23):2690\u20137.","journal-title":"J Clin Oncol"},{"issue":"5","key":"801_CR5","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1177\/1203475419867610","volume":"23","author":"A Sivanand","year":"2019","unstructured":"Sivanand A, Surmanowicz P, Alhusayen R, Hull P, Litvinov IV, Zhou Y, Gniadecki R. Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments. J Cutan Med Surg. 2019;23(5):537\u201344.","journal-title":"J Cutan Med Surg"},{"issue":"24","key":"801_CR6","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1158\/1078-0432.CCR-14-1768","volume":"20","author":"CR Pickering","year":"2014","unstructured":"Pickering CR, et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res. 2014;20(24):6582\u201392.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"801_CR7","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/cup.12728","volume":"43","author":"NA Slater","year":"2016","unstructured":"Slater NA, et al. PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis. J Cutan Pathol. 2016;43(8):663\u201370.","journal-title":"J Cutan Pathol"},{"issue":"4","key":"801_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","volume":"379","author":"MR Migden","year":"2018","unstructured":"Migden MR, et al. PD-1 blockade with Cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341\u201351.","journal-title":"N Engl J Med"},{"issue":"10","key":"801_CR9","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1182\/blood-2009-04-216671","volume":"114","author":"RA Wilcox","year":"2009","unstructured":"Wilcox RA, Feldman AL, et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 2009;114(10):2149\u201358.","journal-title":"Blood."},{"issue":"23","key":"801_CR10","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","volume":"34","author":"AM Lesokhin","year":"2016","unstructured":"Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698\u2013704.","journal-title":"J Clin Oncol"},{"key":"801_CR11","doi-asserted-by":"crossref","unstructured":"Khodadoust M, Rook AH, Porcu P, et al. Pembrolizumab for treatment of relapsed\/refractory mycosis Fungoides and Sezary syndrome: clinical efficacy in a Citn multicenter phase 2 study. Blood. 2016;128.","DOI":"10.1182\/blood.V128.22.181.181"},{"issue":"18","key":"801_CR12","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","volume":"129","author":"C Herbaux","year":"2017","unstructured":"Herbaux C, Gauthier J, Brice P, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. 2017;129(18):2471\u20138.","journal-title":"Blood."},{"issue":"2","key":"801_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","volume":"130","author":"BM Haverkos","year":"2017","unstructured":"Haverkos BM, Abbott D, Hamadani M, et al. PD-1 blockade for relapsed lymphoma postallogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017;130(2):221\u20138.","journal-title":"Blood."},{"issue":"4","key":"801_CR14","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med. 2015;372(4):311\u20139.","journal-title":"N Engl J Med"},{"issue":"15","key":"801_CR15","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.1158\/0008-5472.CAN-11-0108","volume":"71","author":"WJ Norde","year":"2011","unstructured":"Norde WJ, Maas F, et al. PD-1\/PD-L1 interaction contribute to functional T-cell impairment in patients who relapse with cancer after allogenic stem cell transplantation. Cancer Res. 2011;71(15):5111\u201322.","journal-title":"Cancer Res"},{"issue":"4","key":"801_CR16","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1080\/10428194.2017.1344905","volume":"59","author":"P Boddu","year":"2018","unstructured":"Boddu P, Kantarjian H, et al. The emerging role of immune checkpoint based approaches in AML and MDS. Leuk Lymphoma. 2018;59(4):790\u2013802.","journal-title":"Leuk Lymphoma"},{"key":"801_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40425-017-0236-3","volume":"5","author":"S Rosner","year":"2017","unstructured":"Rosner S, Sen F, Postow M. Response after treatment with pembrolizumab in a patient with myelophthisis due to melanoma: the role of checkpoint inhibition in the bone. J Immunother Cancer. 2017;5:34.","journal-title":"J Immunother Cancer"},{"issue":"22","key":"801_CR18","doi-asserted-by":"publisher","first-page":"Abstract 4571","DOI":"10.1182\/blood.V128.22.4571.4571","volume":"128","author":"LK Schoch","year":"2016","unstructured":"Schoch LK, Borrello I, Fuchs EJ, et al. Checkpoint inhibitor therapy and graft versus host disease in allogeneic bone marrow transplant recipients of haploidentical and matched products with post-transplant cyclophosphamide [abstract]. Blood. 2016;128(22):Abstract 4571.","journal-title":"Blood"},{"issue":"1","key":"801_CR19","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","volume":"25","author":"A Ijaz","year":"2019","unstructured":"Ijaz A, Khan AY, Malik SU, et al. Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant. 2019;25(1):94\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"801_CR20","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jaad.2018.05.035","volume":"79","author":"CK Min Lee","year":"2018","unstructured":"Min Lee CK, Li S, Tran DC, Zhu GA, Kim J, Kwong BY, Chang ALS. Characterization of dermatitis after PD-1\/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study. J Am Acad Dermatol. 2018;79(6):1047\u201352.","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"801_CR21","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.ctrv.2010.03.004","volume":"36","author":"A Deol","year":"2010","unstructured":"Deol A, Lum LG. Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat Rev. 2010;36(7):528\u201338.","journal-title":"Cancer Treat Rev"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0801-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0801-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0801-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:46:22Z","timestamp":1601055982000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0801-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["801"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0801-z","relation":{},"ISSN":["2051-1426"],"issn-type":[{"type":"electronic","value":"2051-1426"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"23 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not Applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written and verbal consent were obtained from the patient prior to submission for publication. A copy of the written consent form is available at the editorial office for this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KK reports no conflict of interest. AM reports: kyowa kirin- advisory board, Helsinn- Advisory board, Elorac, Sologenix MiRagen (investigator), investigator in CITN study \u201cembrolizymab and IFN-gamma in MF\/SS and synovial sarcoma\u201d. LC reports no conflict of interest. FD reports no conflict of interest. PW reports no conflict of interest. RF reports no conflict of interest. GA speaker bureau for Merck.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"338"}}